Clinical Outcomes and Mortality among Patients Hospitalized with Hypoglycemia and End-Stage Renal Disease in the U.S.

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 401-P
Author(s):  
RODOLFO J. GALINDO ◽  
CAROLINA R. HURTADO ◽  
FRANCISCO J. PASQUEL ◽  
PRIYATHAMA VELLANKI ◽  
GUILLERMO E. UMPIERREZ
Keyword(s):  
Renal Disease ◽  
Clinical Outcomes ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
The U.S

Clinical outcomes of kidney transplantation in older end‐stage renal disease patients: A nationwide cohort study

2019 ◽  
Vol 19 (5) ◽  
pp. 392-398 ◽  
Author(s):  
Eun Jeong Ko ◽  
Jaeseok Yang ◽  
Curie Ahn ◽  
Myoung Soo Kim ◽  
Duck Jong Han ◽  
...  
Keyword(s):  
Cohort Study ◽  
Kidney Transplantation ◽  
Renal Disease ◽  
Clinical Outcomes ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

What can we learn from the U.S. expanded end-stage renal disease bundle?

Health Policy ◽  
2013 ◽  
Vol 110 (2-3) ◽  
pp. 164-171 ◽  
Author(s):  
James D. Chambers ◽  
Daniel E. Weiner ◽  
Sarah K. Bliss ◽  
Peter J. Neumann
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
The U.S

scholarly journals C3-Glomerulonephritis in New Zealand – A Case Series

2020 ◽  
Author(s):  
Luke J Sutherland ◽  
Hari Talreja
Keyword(s):  
New Zealand ◽  
Renal Impairment ◽  
Renal Disease ◽  
Clinical Outcomes ◽  
End Stage Renal Disease ◽  
Disease Incidence ◽  
Pacific Islanders ◽  
C3 Glomerulonephritis ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background: C3-glomerulonephritis can lead to progressive renal impairment from complement-mediated glomerular injury. Incidence and outcomes of C3-glomerulonephritis are not known in the New Zealand population. Methods: We reviewed all cases of C3-glomerulonephritis from the past 10 years at a tertiary referral centre in New Zealand. Descriptive information on baseline characteristics and clinical outcomes was collected. Results: 26 patients were included (16 men; mean±SD age 44±25 years) with a median follow-up of 30 months. Disease incidence was 1.3 cases per million individuals, of which 42% were Pacific Islanders. Most patients presented with renal impairment, with a median (IQR) creatinine at diagnosis of 210 (146-300) µmol/L, and nephrotic-range proteinuria with a protein/creatinine ratio of 551.5 (293-983) mg/mmol. 8 (31%) patients progressed to end stage renal disease and 2 (8%) had died. End stage renal disease occurred in 25% of patients treated with immunosuppression and in 50% of those not treated. Complete remission was seen in 25% of patients treated with some form of immunosuppression and in 17% of those not treated. Conclusions: Our results are consistent with previous descriptions of C3-glomerulonephritis. There was a suggestion of better clinical outcomes in patients treated with immunosuppression. There was a higher disease incidence in Pacific Islanders, which may indicate an underlying susceptibility to complement dysfunction in this population.

Mo1153 The Clinical Outcomes of Patients With End Stage Renal Disease Requiring Hemodialysis Who Have Digestive Cancers

2013 ◽  
Vol 144 (5) ◽  
pp. S-593
Author(s):  
Hiroaki Fujiwara ◽  
Nobuo Toda ◽  
Tomoharu Yamada ◽  
Mari Yamagami ◽  
Kouki Sato ◽  
...  
Keyword(s):  
Renal Disease ◽  
Clinical Outcomes ◽  
End Stage Renal Disease ◽  
Digestive Cancers ◽  
Stage Renal Disease ◽  
End Stage

Policies Regarding Treatment of End-Stage Renal Disease in the United States and United Kingdom

1986 ◽  
Vol 2 (2) ◽  
pp. 253-274 ◽  
Author(s):  
Susan Klein Marine ◽  
Roberta G. Simmons
Keyword(s):  
United States ◽  
Kidney Transplantation ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Well Being ◽  
The United States ◽  
The Body ◽  
Stage Renal Disease ◽  
End Stage ◽  
The U.S

The treatment of End-Stage Renal Disease (ESRD) represents a victory for medical technology. Dialysis and kidney transplantation, developed in the early 1960s, offer alternative treatments to patients whose own kidneys no longer function; before, these patients faced a terminal diagnosis. Dialysis is a mechanical treatment in which the patient is connected to a machine that cleanses the blood of impurities and returns it to the body. Although recent innovations (e.g., continuous ambulatory peritoneal dialysis—CAPD) facilitate patient independence from a machine, replacement of the diseased kidneys is the most desirable and least expensive treatment for many patients (33;39). Kidney transplantation remains the most effective and common type of transplantation, and a new kidney (from a living-related or cadaver donor) often dramatically improves the recipient's health and general well-being (20;39). Now, in the mid-1980s, these technologies are no longer new and innovative. Further analysis of these established but costly technologies provides a perspective on the long-range implications of innovations in patient care: while some new issues have emerged, many problems originally associated with these treatments seem to have intensified. Access to treatment remains a central issue, closely linked to the dilemma of equity versus cost. The contrast in the access provided by the United States and Great Britain is dramatic (40); in 1982, the rate of ESRD treatment within the U.S. was twice that of the U.K. (353 versus 160 patients per million) (37). The U.S. policy is basically one of unlimited access, whereas the U.K. has restricted access.

scholarly journals FP531REAL-WORLD TREATMENT AND CLINICAL OUTCOMES IN END-STAGE RENAL DISEASE PATIENTS WITH SEVERE HYPERKALEMIA UNDERGOING HEMODIALYSIS IN THE UNITED STATES

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i218-i218
Author(s):  
Dinesh Chatoth ◽  
Peter Wahl ◽  
Viatcheslav Rakov ◽  
Carly Van Zandt ◽  
Kathryn Anastassopoulos ◽  
...  
Keyword(s):  
United States ◽  
Renal Disease ◽  
Clinical Outcomes ◽  
End Stage Renal Disease ◽  
The United States ◽  
Severe Hyperkalemia ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document